Table 1.
Patient baseline clinical characteristics.
| Number | 66 |
| Age (years) | 56 ± 13 |
| Males, n (%) | 56 (85) |
| Ischemic etiology n, (%) | 24 (36) |
| Diabetes mellitus n, (%) | 13 (20) |
| Arterial Hypertension n, (%) | 31 (47) |
| Atrial Fibrillation n, (%) | 5 (8) |
| NYHA class II, n (%) | 49 (76) |
| III, n (%) | 17 (24) |
| BMI (kg/m2) | 29.4 ± 6.2 |
| SAP (mm Hg) | 120 ± 15 |
| Heart rate (beats/minute) | 67 ± 9 |
| LVEF (%) | 29 ± 6 |
| Creatinine (mg/dL) | 0.99 ± 1.9 |
| GFR-EPI (mL/min/1.73 m2) | 84 ± 22 |
| NT-proBNP (pg/mL) | 1052 ± 1321 |
| Concomitant therapy at the enrollment | |
| ACE-I, n (%) | 45 (68) |
| Enalapril-equivalent dose (mg/die) | 11 ± 6 |
| ACE-I ≥ 50% target dose n (% among treated) | 32 (71) |
| ARB, n (%) | 21 (32) |
| Valsartan-equivalent dose (mg/die) | 138 ± 75 |
| ARB ≥ 50% target dose (% among treated) | 11 (55) |
| Beta-blockers (%) | 65 (98) |
| Bisoprolol-equivalent dose (mg/die) | 7.1 ± 3.2 |
| Beta-blocker ≥ 50% target dose | 50 (76) |
| MRA n, (%) | 58 (88) |
| MRA dose | 45 ± 26 |
| Loop diuretics n, (%) | 52 (79) |
| Furosemide-equivalent dose (mg/die) | 76 ± 102 |
| ICD, n (%) | 61 (95) |
| CRT, n (%) | 22 (34) |
| Sacubitril/Valsartan up-titrated dose | |
| 24/26 mg b.i.d., n (%) | 34 (51) |
| 49/51 mg b.i.d., n (%) | 22 (34) |
| 97/103 mg b.i.d., n (%) | 10 (15) |
ACE-I: inhibitors of Angiotensin-Converting Enzyme; ARB: angiotensin II receptor blockers; BMI: body mass index; GFR-EPI: estimated glomerular filtration rate by EPI formula; CRT: cardiac resynchronization therapy; ICD: implantable cardioverter-defibrillator; LVEF: left ventricular ejection fraction; MRA: mineralcorticoid receptor antagonists; NYHA class: New York heart Association class; NT-proBNP: amino terminal brain natriuretic peptide; SAP: systolic arterial pressure.